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Abstract 
Background: Clinical diagnoses of fungal infections often rely upon culture techniques followed by microscopic 
examination of positive cultures and histopathological specimens. Culturing of microorganisms is prone to false nega-
tives, while microscopy methods can be complicated by atypical phenotypes and organisms that are morphologically 
indistinguishable in tissues. Delays in diagnoses (or the lack thereof ) and inaccurate identification of infectious organ-
isms contribute to increased morbidity and mortality in patients.
Methods: Two-hundred randomized, heterogeneous patient blood and respiratory samples that were culture-nega-
tive were tested using polymerase chain reaction (PCR) amplification of internal transcribed spacer regions of riboso-
mal RNA genes utilizing panfungal primers. Amplicons were sequenced, subjected to sequence similarity searches, 
and compared using phylogenetic analyses.
Results: Thirteen fungal sequences were detected in three whole-blood samples and nine respiratory samples. Bio-
informatic analyses were performed which indicated the presence of multiple pathogens and potential pathogens.
Conclusions: The results from this pilot study demonstrate the utility of PCR assays and sequence analyses in clinical 
tests for fungi to facilitate rapid diagnosis and appropriate treatments to deal with the false negatives from culture 
results.
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Background
Invasive aspergillosis (IA) and invasive candidiasis (IC) 
are two of the most frequently encountered opportunis-
tic fungal diseases in immunocompromised individuals 
and are also two of the most frequent nosocomial fungal 
infections [1–8]. In addition, the emergence of normally 
non-pathogenic fungi as causative agents of disease has 
become a serious concern with increases of transplant 
surgeries [7], immunosuppressive therapies [9], individu-
als with HIV/AIDS [10, 11], and patients with underlying 
primary diseases such as hematological malignancies and 
cancer [12]. Multiple-cause-of-death records from the 
period 1980–1997 reported that multiple-cause mortal-
ity due to invasive mycoses increased over 300 % and that 
mortality from IA increased over 350  % [13]. Further-
more, non-Aspergillus fungal infections in organ trans-
plant patients have increased and resulted in increases of 
morbidity and mortality [14].
Increases in opportunistic fungal infections and 
immunocompromised populations have led to the need 
to accurately identify fungal pathogens rapidly and spe-
cifically. Patient morbidity and mortality statistics show 
that delays in diagnosis and appropriate treatment con-
tribute significantly to poor prognoses [15]. Consensus 
from the international community for diagnostic cri-
teria for proven, probable, and possible invasive fungal 
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infections (IFI) has been recalcitrant [5, 16]. Tradition-
ally, IFI have been characterized from phenotypic iden-
tification based on positive cultures or from histology of 
body sites [17].
Several problems exist with these approaches. First, 
patients with suspected infections may not be healthy 
enough for invasive biopsy procedures due to immuno-
suppressive therapies or other conditions [9, 11]. Physical 
trauma to skin from biopsies, and subsequent exposure to 
nosocomial pathogens presents inherent risks for addi-
tional infections. In addition, misidentification of fungi, 
or failure to identify any causative microorganisms, in 
histological and cytological samples [18, 19] present criti-
cal challenges to prompt and appropriate treatment. Non-
invasive procedures such as computed tomography (CTs) 
or X-rays may fail to reveal mycetomas and nephrotic 
lesions promptly enough for effective treatment. In addi-
tion, high proportions of false-negative results in clinical 
tests are possible, with reported sensitivities of 8.3 [20] to 
31 % [21]. Emerging variants of pathogenic and assumed 
non-pathogenic fungi may be overlooked. Cultures may 
also exhibit atypical morphology [22, 23], multiple mor-
phologies, or require lengthy incubations of several weeks 
or more for colony growth [24], as well as expert interpre-
tations. Finally, the presence of more than one species in 
a sample may contribute to a culture-negative interpreta-
tion [25].
Aim of this study
The present study retrospectively tested randomly cho-
sen blood and respiratory samples that were reported to 
be culture-negative for bacterial and fungal pathogens. 
The specific objectives were to amplify ribosomal DNA 
(rDNA) internal transcribed spacer (ITS) regions by 
polymerase chain reaction (PCR) using panfungal ITS 
primers, sequence the major amplicons, compare PCR-
positive samples to patient information (such as age and 
gender) to identify associations between potential fungal 
pathogens and subsets of heterogeneous, randomized 
patient populations, and finally to perform phylogenetic 
analysis to infer taxonomic classifications for each of the 
fungal sequences found. ITS regions have been used to 
delineate fungi to the species level, and often the strain 
level [23, 26, 27]. A relatively innovative characteris-
tic of this research is that rather than targeting specific 
patients based upon known patient demographics or 
other risk factors associated with increased incidence 
of fungal infection [28, 29], molecular testing for fungal 
infections was performed on randomly chosen patients. 
The primary aim of this study was to determine whether 
the utilization of standard molecular techniques (spe-
cifically PCR amplification and sequencing of rDNA 
ITS regions) could provide essential improvements to 




Samples were collected aseptically by hospital personnel at 
the University of Michigan Hospital Clinical Microbiology 
and Virology Laboratories (Ann Arbor, MI). After clini-
cal testing (see below) using the BacT/Alert blood culture 
instrument (bioMerieux, Inc.) and standard microbiologi-
cal culture techniques, samples of 100 culture-negative 
blood (for bacteria and fungi) and 100 culture-negative 
(for bacteria) respiratory samples were collected for study 
that were obtained from randomized patients in heteroge-
neous populations in the hospital within a 1-year period in 
2005 and 2006. Only one sample was obtained from each 
patient. Approval was obtained from the Human Subjects 
Institutional Review Boards at the University of Michigan 
and Bowling Green State University. The samples were 
deidentified and obtained from discarded microbiol-
ogy laboratory specimens. Because of this, the study was 
exempt from informed consent procedures. The samples 
were immediately transported on ice to the Bowling Green 
State University laboratory and stored at −20 °C. Pre-ster-
ilized single-use needles were used for blood preparations 
and pre-sterilized aerosol-resistant pipet tips were used for 
preparation of respiratory samples. Aliquots were stored at 
−20 °C prior to testing.
Sample and patient information
Thirty-seven of the whole-blood samples had been cul-
tured anaerobically, and 63 had been cultured aerobically 
using BacT/Alert FAN (bioMerieux, Inc.) media by Uni-
versity of Michigan Hospital personnel. Collection vol-
umes ranged between 1 (pediatric) and 10 ml (adult) and 
cultures were held for an average of 5  days before they 
were considered culture-negative for fungal and bacterial 
pathogens. Respiratory samples consisted of bronchoal-
veolar lavage (BAL, n =  25), sinus (n =  1) and sputum 
(n = 74) specimens and had been cultured aerobically by 
University of Michigan Hospital personnel. Volumes col-
lected were between 2 and 10 ml and cultures were con-
sidered negative after 2 days if no growth was observed.
Patient age ranged from less than 1-year old to 91 years 
old. Fifty-nine patients were between the ages of <1–
20 years old (29.5 %), thirty were 21–40 years old (15 %), 
62 were 42–60 years-old (31 %), 42 were 61–80 years old 
(21  %), and seven were 81–91  years-old (3.5  %). One-
hundred and three patients were male (51.5  %) and 97 
patients were female (48.5  %). Most samples (n  =  137) 
were collected from non-Intensive Care Units (68.5  %), 
whereas 63 samples were collected from Intensive Care 
Units (ICU) (31.5 %).
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DNA extraction
A cetyltrimethylammonium bromide (CTAB) DNA 
extraction method [30–33] with slight modifications 
was performed on the samples. This method eliminates 
biomolecules and other chemicals that often inhibit 
PCR (and other) reactions through the utilization of dif-
ferential precipitation steps. Positive controls consist-
ing of blood or respiratory samples to which had been 
added either Aspergillus flavus or Aspergillus fumigatus 
ATCC® MYA-4609™ cells were performed at the same 
time. Additionally, negative controls were included that 
consisted of 200  μl of sterilized reverse osmosis water 
(18.2 MΩ, <1 ppb TOC).
PCR, cloning, and DNA sequencing
Primer combinations (Table 1; Fig. 1) targeting the inter-
nal transcribed spacer 1 (ITS1) region (primer pair ITS2/
ITS5 [34]), the ITS2 region (primer pairs ITS3/ITS4Z or 
ITS4FS [35, 36]), or both regions (primer pairs ITS4Z 
or ITS4FS/ITS5, LS266/V9D) were used to amplify PCR 
products utilizing a Bio-Rad PTC-100 Peltier Thermal 
Cycler (Integrated DNA Technologies, Coralville, IA). 
Reactions consisted of approximately 1–10  ng genomic 
DNA, 20 mM (NH4)2SO4, 50 pmol each primer, 1.5 mM 
MgCl2, 200  μM each dNTP, and two units native Taq 
DNA polymerase (Fermentas, Glen Burnie, MD). The 
PCR program [23, 37] consisted of the following steps: 
95 °C for 1 min, followed by 35 cycles of 94 °C for 1 min, 
annealing temperature (50, 52 or 55  °C) for 4  min, and 
72  °C for 4 min; and then a final extension of 72  °C for 
10 min. PCR products that exhibited robust bands on 1 % 
agarose (in TBE @ 5  V/cm for 1  h) were purified using 
QIAquick PCR purification kits (QIAGEN, Valencia, 
CA), as per the manufacturer’s protocol. Purified eluates 
were confirmed on 1 % agarose gels, and were stored at 
−20 °C.
When PCR products exhibited multiple robust bands 
on 1 % agarose gels, each band was excised and then puri-
fied using a QIAquick Gel Extraction kit, as per manufac-
turer’s protocol. These were cloned into pCR2.1-TOPO 
vectors (TOPO TA Cloning kit for sequencing, Invitro-
gen, Carlsbad, CA), as per manufacturer’s protocol. For 
transformations, 4 μl of cloning products were added to 
a vial of One Shot™ Chemically Competent E. coli cells 
(Thermo Fisher Scientific, Carlsbad, CA), as per manu-
facturer’s protocol, and were spread on Luria–Bertani 
Difco™ LB Agar plates (Becton, Dickson and Company, 
Sparks, MD) with 50 μg/ml ampicillin (Sigma-Aldrich, St. 
Louis, MO) supplemented with 40 μl 5-bromo-4-chloro-
3-indoxyl-beta-d-galactopyranoside (X-gal, 20  mg/ml, 
Gold Biotechnology, St. Louis, MO). Duplicate plates 
were prepared for each sample using 50 or 75 μl of trans-
formed cells and were then incubated overnight at 37 °C.
At least ten recombinant colonies were selected from 
each plate and subcultured on Luria–Bertani agar 
(Difco™ LB Agar) supplemented with 50  μg/ml ampi-
cillin. After overnight incubation, 5–10 colonies were 
selected from each cloning reaction and inoculated into 
4 ml Difco™ LB broth with 50 μg/ml ampicillin and incu-
bated overnight at 37  °C with shaking. Plasmids were 
isolated using the Cyclo-Prep miniprep plasmid DNA 
purification kit (Amresco, Solon, OH).
Plasmids were analyzed for inserts by digestion with 
EcoRI or by PCR amplification reactions containing the 
following components: 1× Taq buffer with (NH4)2SO4 
[750  mM Tris–HCl (pH 8.8) 200  mM (NH4)2SO4, 1  % 
Table 1 Panfungal internal transcribed spacer (ITS) prim-
ers utilized in this study
a N = A, C, G, or T and R = A or G
Primer name Sequence (5′–3′) Reference
ITS2 GCTGCGTTCTTCATCGATGC 20
ITS3 GCATCGATGAAGAACGCAGC 20
ITS4FS TCCTCCGCTTATTNATATGCa F. Sidiq, unpublished





V9D ITS5 ITS1 ITS3 
ITS2 
SSU LSU 
SSU LSU 5.8S ITS1 ITS2 
ITS4 
Fig. 1 Locations for the panfungal primers in the rDNA internal transcribed spacer (ITS) region. Arrows indicate locations and orientations of primers 
used in this study. SSU and LSU represent the small and large rRNA gene subunits, respectively. Primer sequences are provided in Table 1
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Tween 20], 200  μM each dNTP, 1.25 units native Taq 
DNA polymerase (Fermentas, Inc., Glen Burnie, MD), 
1.5 mM MgCl2 and 50 pmol of M13 primers [M13F(−20): 
GTAAAACGACGGCCAG, M13 reverse: CAGGAAA 
CAGCTATGAC]. PCR was performed using the follow-
ing program: 95 °C for 4 min, 30 cycles of 95 °C for 1 min, 
45 °C for 2 min, 72 °C for 2 min, and a final extension at 
72 °C for 10 min. All purified PCR and plasmid isolations 
were commercially sequenced by Geneway, LLC (Hay-
ward, CA, USA) using Sanger sequencing methods.
Bioinformatic analyses of sequences
The resulting ITS sequences were compared to Gen-
Bank entries in the National Center for Biotechnology 
Information (NCBI) database. BLASTn was used with 
default parameters and sequences with at least 96  % 
maximum identity were aligned with sequences from 
the blood and respiratory samples using MAFFT ver-
sion 5.7 [38] from the bioinformatics toolkit at the Max 
Planck Institute for Developmental Biology (http://www.
toolkit.tuebingen.mpg.de/sections/alignment). Refer-
ence sequences were collected if they were from pub-
lished studies and had been identified to at least the 
species level. Multiple sequence alignments were visu-
ally inspected and curated for subsequent analyses. Phy-
logenetic analysis was performed with MEGA v. 6 [39] 
using maximum likelihood and neighbor-joining, with a 
maximum composite likelihood model. Since phyloge-
netic reconstructions from each method have differing 
underlying assumptions, congruent trees derived from 
the two methods increased confidence in tree topology 
[40]. Bootstrap analysis (1000 replications) was also per-
formed as a measure of support for tree nodes [41]. The 
best-fit nucleotide substitution model, based on the cor-
rected Akaike (AICc) and Bayesian Information Criteria 
(BIC), was determined. For sequences corresponding to 
the ITS1 region, hierarchical likelihood ratio tests ascer-
tained that the Kimura 2-Parameter substitution model 
with invariant rate differences among sites was the opti-
mal evolutionary model for phylogenetic inference. For 
sequences corresponding to the ITS2 region, as well as 
both regions, the Jukes-Cantor substitution model with 
gamma-distributed rate differences among sites was 
determined as the best-fit evolutionary model for phylo-
genetic reconstruction.
Statistical analyses
Statistical analyses were conducted with Minitab v. 17. 
Unpaired t tests were used to compare means of patient 
length of stay (LOS) or age for PCR-positive samples to 
PCR-negative samples. Additionally, Fisher’s exact test 
with a 2  ×  2 contingency table was used for categori-
cal data to compare the frequency of patients in ICU for 
PCR-positive patients and PCR-negative patients, as well 
as the frequency of male and female patients.
Results
Fungal DNA was detected in nine of the 100 respiratory 
culture-negative samples and three of the 100 whole-
blood culture-negative samples (Table  2). Sample type, 
patient sex, age, location in the hospital, putative fungal 
type, maximum identity, and sequence lengths compared 
are summarized in Table 2. Seven of the twelve samples 
that were positive for fungal DNA were from patients in 
an ICU. However, none of the variables, including pres-
ence in the ICU, patient LOS, sex, or age differed signifi-
cantly with respect to the presence or absence of fungal 
DNA (Fisher’s exact p values  =  0.054–0.136). A com-
bination of BLASTn and phylogenetic reconstructions 
provided indications of the taxa closest to those deter-
mined from the patient samples. Maximum likelihood 
and neighbor-joining methods generally confirmed the 
taxonomic relationships inferred by the BLASTn results 
(Figs.  2, 3, 4). In most instances, high bootstrap val-
ues (>80) provided confidence for nodes that clustered 
observed sequences with reference sequences. The taxa 
closest to the sequences in blood specimens included 
Lecanicillium kalimantanense, Cladosporium cladospori-
oides, and Fusarium graminearum. The taxa closest to the 
sequences from respiratory samples included four exam-
ples of Candida albicans, Aspergillus flavus, Aspergil-
lus fumigatus, Engyodontium album, Candida glabrata, 
Alternaria alternata and Aureobasidium pullulans.
Discussion
Increases in fungal infections, including increasing 
diversity in the species infecting immunocompromised 
patients, as well as difficulties in rapidly diagnosing fun-
gal infections, requires that additional vigilance and more 
sensitive methods be broadly adopted in order to affect 
rapid and accurate diagnoses and targeted treatments. 
This is especially important in cases where the fungi are 
able to disseminate into multiple tissues where effective 
therapies become more difficult and dangerous. Fungal 
infections can initially appear similar to bacterial infec-
tions. However, antibiotic treatment is contraindicated 
for fungal infections because it may further weaken a 
patient, or exacerbate the fungal infection, by causing 
the reduction in the number of beneficial bacterial spe-
cies. Molecular methods are effective in rapid detection 
of fungal infections. They can be valuable additions to the 
diagnostic tools available to assess the causative organ-
isms in diseased individuals.
The molecular biology methods used here allowed the 
detection of sequences from pathogenic and potentially 
pathogenic fungi in 6.5 % (13 of 200) of the culture-negative 
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specimens. Furthermore, the sequence analyses were suffi-
cient to allow the determination of fungi to at least the level 
of genus, with identity values of 96–100 % over lengths of 
201–850  bp (Table  2). The rDNA ITS regions have been 
successfully used in taxonomic and phylogenetic stud-
ies to circumscribe taxa at the levels of genus and species, 
and in some cases to the variety/isolate/strain levels [e.g., 
23, 26, 27]. Most of the species identified are clinically rel-
evant, while a few are unknown to produce symptoms in 
humans, or might be the causes of unrecognized symp-
toms. For example, species of Aspergillus and Aureoba-
sidium are known human pathogens. All of the specimens 
that were positive for species in these two genera exhibited 
99–100 % identity over 232–274 bp, and thus are likely to 
be the species indicated (i.e., Aspergillus flavus, A. fumiga-
tus, and Aureobasidium pullulans). A large number of the 
fungus-positive specimens exhibited sequences closest to 
species that have been reported in immunocompromised 
patients. These were: specimen 235 (100 % over 217 bp to 
Fusarium graminearum); specimen 406 (100 % over 215 bp 
to Cladosporium cladosporioides); specimens 527, 533, 626, 
and 632a (99–100 % identities over 236–562 bp to Candida 
albicans); specimen 632b (98  % over 860  bp to Candida 
glabrata); and specimen 802 (96  % sequence identity of 
Table 2 Summary of  patient characteristics and  taxonomic affinities of  fungi in  the samples based on  ITS1 and  ITS2 
sequences
BAL bronchoalveolar lavage
a Arthropod-associated; Occasional infections in immunocompromised patients [42]
b Documented infections of immunocompromised patients
c Human pathogen
d Two separate prominent sequences were recovered from patient 632 (632a and 632b)
Patient ID (Accession #) Patient characteristics Sample source Putative taxa Identity (%)/# bp
Sex Age Location
223 (KF798202) Female 57 Hematology/oncology Blood Lecanicillium kalimantanensea 96/827
235 (FJ223846) Female 62 Dermatology Blood Fusarium graminearumb 100/217
406 (FJ223846) Female <1 Neonatal ICU Blood Cladosporium cladosporioidesb 100/215
527 (KF803254) Male 44 Medical ICU BAL Candida albicansb 99/509
533 (KF803255) Male 21 Pulmonary Sputum Candida albicansb 99/444
534 (KF825543) Male 68 Medical ICU Sputum Aspergillus flavusc 100/236
611 (KF825542) Female 52 Medical ICU BAL Aspergillus fumigatusc 100/232
612 (KF825546) Female 77 Medical ICU BAL Aureobasidium pullulansb 99/274
614 (KF825545) Female 54 Cardiology ICU Sputum Engyodontium albumb 98/201
626 (KF803256) Female 75 Cardiology Sputum Candida albicansb 100/560
632ad (KF803257) Female 73 Pulmonary Sputum Candida albicansb 100/562
632bd (KF825541) Female 73 Pulmonary Sputum Candida glabratab 98/860
802 (KF825544) Female 20 Medical ICU Sputum Alternaria alternatab 96/426

















Fig. 2 Maximum likelihood phylogenetic tree derived from align-
ments of ITS1 sequences. The best-fit nucleotide substitution model 
for the sequence dataset, based on the corrected Akaike (AICc) and 
Bayesian Information Criteria (BIC), was determined using MEGA v. 
6 [39]. Hierarchical likelihood ratio tests ascertained that the Kimura 
2-Parameter substitution model with invariant rate differences among 
sites was the optimal evolutionary model for phylogenetic inference. 
Fungal sequences collected from samples are in bold black font, 
labeled with the patient ID followed by NCBI (GenBank) accession 
numbers in parentheses. Genus and species are provided for the refer-
ence sequences. Red font indicates a known human pathogen, and 
blue font indicates species that have been documented as opportun-
istic pathogens in immunocompromised patients. Bootstrap values 
(1000 replications) are provided to indicate support levels for tree 
nodes. Unlabeled branches have bootstrap values below 50 %. Speci-
men type: [L] = BAL bronchoalveolar lavage, [S] sputum
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426 bp to Alternaria alternata). While 98–100 % sequence 
identities likely indicate that the species designations accu-
rately identify the fungus in the sample, sequence identities 
≤97 % are indications that the sequences represent closely 
related fungal species, possibly within the same genus, but 
not necessarily the fungus whose sequence matched on 
the NCBI (GenBank) sequence database. This is the case 
for the sequence from specimen 802, which most closely 
matched Alternaria alternata, as well as the sequence from 
specimen 223, which was closest to the Lecanicillium kali-
mantanense sequence from the sequence database. The lat-
ter species is most often found on arthropods, but has been 
reported as a possible human pathogen [42]. It is likely that 
the sequence from specimen 223 is from a related species 
whose sequence is not yet represented in the database. 
Whether this is a common species, whether it has been 
described scientifically, or whether it is a human pathogen, 
are unknown.
The greater percentage of PCR-positive results from 
ICU patient samples compared to total patients concurs 
with reports that identify increased instances of fungal 
infections in ICUs [43]. In contrast, the greater levels of 
PCR-positive female patients relative to females among 
the total population of subjects studied is contrary to 
previous studies [44]. However, none of the associations 
with any of the variables, including presence in the ICU, 
sex, age, or LOS, was statistically supported. Therefore, 
according to the statistical analyses, there appeared to be 
no association of the presence of fungal DNA related to 
any of the variables. Therefore, the most important find-
ing is that the molecular methods employed were more 
sensitive and faster than are culture methods, regardless 
of the variables considered in this research.
A relatively novel aspect of this study is that rather than 
target specific populations for molecular analyses with a 
priori knowledge of patient factors already associated with 
increased incidence of fungal infection [28, 29], molecular 
testing was performed devoid of patient information and 
results were then compared with patient data. The blind 
nature of this study demonstrated the sensitivity of molec-
ular techniques that can be included in diagnostic settings, 
with less training than is necessary for specialized tech-
nicians who identify fungi based on phenotypic growth. 
Hence, the methods utilized in this report are potentially 
translatable to the clinical setting. In fact, much of the pro-
tocol can be automated, thus increasing consistency and 
decreasing the time and expense for each assay.
The findings of this study support the premise that 
molecular analyses provide sensitive and rapid detec-
tion of pathogens [2, 24, 29], including in those situations 
where other methods (e.g., culturing) are inadequate 
for the rapid detection of a diversity of organisms. The 
relatively inexpensive methods, open-source data inves-
tigation, and potential for high-throughput analyses of 
various tissue samples suggest that the methods pre-
sented in this study are prospectively translatable to a 
clinical setting. Additionally, identification can be accom-
plished in much less time (1–2  days) than with culture 
methods (1–2  weeks). The decreased time to diagnosis 
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Fig. 3 Maximum likelihood phylogenetic tree derived from align-
ments of ITS2 sequences. The best-fit nucleotide substitution model 
for the sequence dataset, based on the corrected Akaike (AICc) and 
Bayesian Information Criteria (BIC) was determined using MEGA v. 6 
[39]. Hierarchical likelihood ratio tests ascertained that the Jukes-
Cantor substitution model with gamma-distributed rate differences 
among sites was the optimal evolutionary model for phylogenetic 
inference. Fungal sequences collected from samples and reference 
sequences are labeled as in Fig. 2. Bootstrap support values are indi-
cated as in Fig. 2. Specimen type: [B] blood, [L] = BAL bronchoalveolar 
lavage, [S] sputum
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Fig. 4 Maximum likelihood phylogenetic tree derived from align-
ments of ITS1 and ITS2. The best-fit nucleotide substitution model 
for the sequence dataset, based on the corrected Akaike (AICc) and 
Bayesian Information Criteria (BIC). Hierarchical likelihood ratio tests 
ascertained that the Jukes-Cantor substitution model with gamma-
distributed rate differences among sites was the optimal evolutionary 
model for phylogenetic inference. Fungal sequences collected from 
samples and reference sequences are labeled as in Fig. 2. Green font 
indicates species that have been isolated from arthropod pathogens, 
but have occasionally been associated with human infections in 
immunocompromised patients [42]. Bootstrap support values are 
indicated as in Fig. 2. Specimen type: [B] = blood; [L] = BAL bron-
choalveolar lavage, [S] sputum
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has the potential to reduce morbidity and mortality. 
This study provides insights into the potential number 
of false-negatives in culture-dependent investigations 
of fungal infections reported elsewhere. For example, a 
recent report of fungal infections within a network of 22 
hospitals found that, of the 7759 fungal blood cultures 
performed from 2004 to 2013, 97 were positive for fungal 
species (1.25 %) [44]. Culturing methods were similar to 
those reported within this study. If 6.5 % of the culture-
negative specimens contained fungi (as per the results 
presented here), then potentially a large number of false-
negatives may occur annually. Molecular testing of the 
millions of culture-negative samples in the US could lead 
to the detection and prompt appropriate treatment of 
patients infected by pathogenic fungi. Thus, the results 
reported within this study demonstrate the potential for 
molecular diagnostics to enhance the sensitivity of fungal 
detection, and therefore, improve patient outcomes.
Conclusions
Polymerase chain reaction amplification coupled with 
DNA sequencing can provide valuable diagnostic infor-
mation for patients whose specimens have resulted in 
negative results from culturing assays. The tests provide 
valuable and rapid information, and have the potential to 
reduce morbidity and mortality.
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